Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
Chronic illnesses like depression and cancer can affect social commitments due to unpredictable symptoms and invisible ...
Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...
Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
The drug is already approved in many countries for other lymphoma conditions and is marketed as Epkinly in the U.S. and ...
Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...
AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging ...
On 7 January 2026, Genmab A/S announced a partnership with Anthropic to deploy custom Claude-powered AI agents to accelerate ...
Sheldon Ekirch spends a lot of time on hold with her health insurance company. Sometimes, as the minutes tick by and her frustration mounts, Ekirch, 30, opens a meditation app on her phone. Patients ...
This encyclopedic article outlines evidence-based laboratory tests that are most useful for establishing individualized ...
Nivolumab plus AVD significantly improves PFS compared to brentuximab vedotin plus AVD in advanced-stage classic Hodgkin lymphoma, with a 91% vs 82% 3-year PFS rate. The PFS benefit of nivolumab plus ...
MyChesCo on MSN
New Incyte drug combo shows power against deadly lymphoma
WILMINGTON, DE — Incyte (Nasdaq: INCY) on Thursday unveiled breakthrough results from a pivotal late-stage cancer trial that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback